| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Product revenues | 1,456.12 | 1,469.08 | 1,204.66 | 1,046.15 | 913.10 | 971.68 | 1,038.26 | 985.68 | 917.60 | 856.45 |
| Total Revenues | 1,456.12 | 1,469.08 | 1,204.66 | 1,046.15 | 913.10 | 971.68 | 1,038.26 | 985.68 | 917.60 | 856.45 |
| Cost of sales | 1,089.69 | 1,117.45 | 931.01 | 742.52 | 644.99 | 683.35 | 743.65 | 674.57 | 622.56 | 580.07 |
| Gross Profit | 366.43 | 351.62 | 273.65 | 303.63 | 268.10 | 288.34 | 294.61 | 311.11 | 295.04 | 276.38 |
| Impairment of goodwill | -- | 19.51 | -- | -- | -- | -- | -- | -- | -- | -- |
| Impairment of intangible assets and property and equipment | 2.50 | -- | 6.29 | -- | -- | -- | -- | -- | -- | -- |
| Research and development expenses | 88.70 | 94.36 | 85.72 | 75.21 | 81.97 | 91.03 | 98.66 | 94.52 | 79.58 | 69.21 |
| Research and development reimbursements | -- | -- | -- | -- | (13.93) | (18.56) | (18.76) | (12.04) | (6.66) | (9.61) |
| Selling, general and administrative | 155.11 | 155.58 | 132.69 | 109.55 | 105.04 | 118.68 | 127.15 | 130.52 | 115.25 | 95.46 |
| Restructuring expenses | 13.11 | 4.74 | 0.64 | 3.86 | 5.80 | 12.92 | 14.77 | -- | -- | -- |
| Acquisition transaction expenses | -- | -- | -- | -- | -- | -- | -- | 0.79 | 0.74 | -- |
| Gain on disposal of property and equipment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 259.42 | 274.19 | 225.34 | 188.63 | 178.89 | 204.08 | 221.82 | 213.79 | 188.92 | 155.06 |
| Operating Income (Loss) | 107.02 | 77.44 | 48.31 | 115.01 | 89.22 | 84.26 | 72.79 | 97.32 | 106.12 | 121.32 |
| Interest expense | 15.30 | 14.64 | 4.29 | 2.76 | 4.56 | 4.76 | 4.94 | 4.89 | 3.26 | 2.61 |
| Impairment loss | -- | -- | -- | -- | -- | 22.79 | 11.48 | -- | -- | -- |
| Income (Loss) from equity investment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Minority interest in subsidiary | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt retirement expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other Income (Expenses) | 0.95 | (1.93) | 1.15 | 0.12 | 2.34 | 0.12 | 1.13 | (0.08) | (0.11) | 0.26 |
| Foreign currency gain | 9.60 | (5.92) | (6.78) | 1.49 | (5.44) | 2.33 | 0.62 | (23.11) | 7.81 | 1.12 |
| Gain on settlement of lawsuit | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.95 |
| Revaluation of derivatives | -- | -- | -- | -- | -- | -- | -- | -- | -- | (1.10) |
| Earnings (Loss) Before Income Tax | 102.27 | 54.95 | 38.38 | 113.85 | 81.56 | 59.15 | 58.12 | 69.26 | 110.56 | 128.94 |
| Income tax expense (benefit) | 37.32 | 14.61 | 13.94 | 20.42 | 21.87 | 21.65 | 16.22 | 34.03 | 33.97 | 33.55 |
| Current income tax expense: Federal | -- | -- | -- | 1.94 | 0.78 | 0.26 | 0.34 | 4.14 | 9.22 | 8.43 |
| Current income tax expense: Foreign | -- | -- | -- | 18.39 | 20.15 | 17.67 | 9.22 | 24.67 | 32.84 | 24.62 |
| Provision (Benefit) For Income Taxes: Deferred | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Deferred income tax expense (benefit): Federal | -- | -- | -- | (4.40) | (2.30) | (2.49) | (1.42) | 15.21 | (10.60) | (3.05) |
| Deferred income tax expense (benefit): Foreign | -- | -- | -- | 4.34 | 3.12 | 6.11 | 8.13 | (12.45) | 2.50 | 3.12 |
| Current income tax expense: State and local | -- | -- | -- | 0.23 | 0.08 | 0.09 | (0.07) | 0.15 | 0.75 | 0.61 |
| Provision (benefit) for income taxes: Currently payable | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Deferred income tax expense (benefit): State and local | -- | -- | -- | (0.09) | 0.03 | 0.00 | 0.02 | 2.31 | (0.74) | (0.18) |
| Consolidated Net Income (loss) | 64.95 | 40.34 | 24.44 | 93.43 | 59.69 | 37.51 | 41.90 | 35.23 | 76.60 | 95.39 |
| Loss attributable to non-controlling interest | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income attributable to Gentherm Incorporated | -- | -- | -- | -- | -- | -- | -- | -- | -- | 95.39 |
| Convertible preferred stock dividends | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| DEEMED DIVIDEND TO PREFERRED SHAREHOLDERS | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Income (loss) Available to Common Shareholders | 64.95 | 40.34 | 24.44 | 93.43 | 59.69 | 37.51 | 41.90 | 35.23 | 76.60 | 95.39 |
| Loss before extraordinary item | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | 2.08 | 1.23 | 0.74 | 2.82 | 1.83 | 1.13 | 1.17 | 0.96 | 2.10 | 2.65 |
| Loss before extraordinary item | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | 2.06 | 1.22 | 0.73 | 2.79 | 1.81 | 1.13 | 1.16 | 0.96 | 2.09 | 2.62 |
| Weighted Average Shares Outstanding (Basic) | 31.29 | 32.78 | 33.13 | 33.09 | 32.67 | 33.12 | 35.92 | 36.72 | 36.45 | 36.03 |
| Weighted Average Shares Outstanding (Diluted) | 31.48 | 33.07 | 33.50 | 33.51 | 33.03 | 33.30 | 36.18 | 36.81 | 36.60 | 36.48 |